MV

Marc Voigt

CEO

Immutep Limited

Berlin, Berlin


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Immutep Limited
Industry
research
Employees
52.0
Seniority
C suite
Annual Revenue
1500000.0

Technologies

Gmail Google Apps Vimeo Apache Mobile Friendly YouTube Google Tag Manager Google Analytics Render Remote Basis AI Data Analytics SAP

Keywords

biotechnology: pharmaceutical preparations health care biotechnology research lag-3 immunotherapy cancer treatment autoimmune disease clinical trials eftilagimod alpha immune system therapeutic pipeline mhc class ii checkpoint inhibitors anti-lag-3 antibodies t cell regulation apc activation dendritic cells soluble lag-3 protein autoimmunity bavencio keytruda her2-neu soft tissue sarcoma breast cancer lung cancer monotherapy combination therapy clinical efficacy safety trials phase i trial phase ii trial phase iii trial targeted therapy biotechnology disease modulation regulatory clearance patient enrollment treatment advancements immune checkpoint therapy therapeutic candidates pharmaceutical research innovative biotherapy clinical outcomes patient wellbeing therapeutic innovations cancer biomarkers immune response long-term survival investigator-initiated trials biopharmaceutical developments clinical research biotech industry patient treatments health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans